Gyre Therapeutics, Inc. (GYRE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Gyre Therapeutics, Inc. (GYRE) closed at USD 6.40 on 2026-10-15, a change of -15.1 % over the past year, with a market capitalization of USD 644.69M.

Gyre Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Gyre Therapeutics, Inc. key figures

Previous close

USD 6.40 (2026-10-15)

1-year change

-15.1 %

Market cap

USD 644.69M

Enterprise value

USD 630.3M

P/E ratio (trailing)

-24.32

P/E ratio (forward)

101.33

EPS (trailing)

-0.25

EPS (forward)

0.06

PEG ratio

n/a

Price to book

5.97

Revenue growth

-2.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.40

Employees

625

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Gyre Therapeutics, Inc. and compare it with other stocks.